08:15 EDT Kymera Therapeutics (KYMR) files automatic mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics reports Q3 EPS (82c), consensus (84c)
- Kymera doses first patient in Phase 1 trial of KT-621
- Kymera Therapeutics announces three presentations at EOTC-NI-AACR
- Kymera Therapeutics announces FDA clearance of IND application for KT-621
- Kymera Therapeutics price target raised to $56 from $52 at Oppenheimer
Questions or Comments about the article? Write to editor@tipranks.com